CN Patent

CN116848127A — 缀合寡核苷酸化合物、其制备方法和用途

Assigned to E Therapeutics PLC · Expires 2023-10-03 · 3y expired

What this patent protects

本发明提供适用于治疗用途的新型缀合寡核苷酸化合物。此外，本发明提供制备这些化合物的方法，以及使用此类化合物用于治疗各种疾病和病症的方法。

USPTO Abstract

本发明提供适用于治疗用途的新型缀合寡核苷酸化合物。此外，本发明提供制备这些化合物的方法，以及使用此类化合物用于治疗各种疾病和病症的方法。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN116848127A
Jurisdiction: CN
Classification: —
Expires: 2023-10-03
Drug substance claim: No
Drug product claim: No
Assignee: E Therapeutics PLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.